Novel Caval Valve Implantation in a Patient With Symptomatic Tricuspid Regurgitation and Right Heart Failure.

BACKGROUND: Tricuspid regurgitation (TR) is crucial for recurrent cardiac decompensation. Heterotopic transcatheter approaches enable symptomatic treatment of TR in patients who are ineligible for surgery or transcatheter edge-to-edge repair. The TRICENTO G2 prosthesis is a transcatheter bicaval valved stent graft, not yet approved for the market. FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: To the best of our knowledge, this is the first published case of successful TRICENTO G2 transcatheter heart valve implantation, performed as compassionate use in an 81-year-old man with symptomatic TR following multiple interventions. No major complications occurred during the procedure, and a short-term functional improvement in right ventricular function resulted. Given intermittent third-degree atrioventricular block, leadless pacemaker implantation was conducted subsequently. DISCUSSION: The TRICENTO G2 represents a promising treatment option for symptomatic TR. However, wise patient selection and vigilant postprocedural observation are essential. NOVELTY: The implementation of the TRICENTO G2 may expand our interventional armamentarium for treating TR. TAKE-HOME MESSAGE: The TRICENTO G2 may improve tailored treatment of patients with symptomatic TR and right ventricular dysfunction who are ineligible for approved interventions.